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NeurodegenerationImpaired mitochondrial function has been well documented in Huntington's disease. Mutant huntingtin is
found to affect mitochondria via various mechanisms including the dysregulation of gene transcription and
impairment of mitochondrial function or trafﬁcking. The lengthy and highly branched neuronal processes
constitute complex neural networks in which there is a large demand for mitochondria-generated energy.
Thus, the impaired mitochondrial trafﬁcking in neuronal cells may play an important role in the selective
neuropathology of Huntington's disease. Here we discuss the evidence for the effect of the Huntington's
disease protein huntingtin on the intracellular trafﬁcking of mitochondria and the involvement of this
defective trafﬁcking in the pathogenesis of Huntington's disease.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Huntington's disease (HD) is a dominant, progressive neurode-
generative genetic disease that is caused by a CAG triplet repeat
expansion (N35 CAGs) in the ﬁrst exon of the gene encoding the
huntingtin (htt) protein. HD is characterized by uncontrolled move-
ment, dementia, emotional disturbance, and early death, which often
occur in middle age. These symptoms are associated with the
neuronal loss that occurs preferentially in medium spiny neurons of
the striatum and also extends to other brain regions during the late
stages. The preferential degeneration of striatal neurons can be
reproduced by administration of the mitochondrial toxins in different
animal models, leading to the prevalent theory that mitochondrial
dysfunction contributes to the pathogenesis of HD. In support of this
idea, many recent studies have demonstrated that mutant htt affects
the function of mitochondria in various HD cellular and animalmodels
[1]. The negative impact of mutant htt on mitochondria appears to
result from the indirect effects of mutant htt on the nuclear expression
of genes important for the biogenesis of mitochondria and the direct
effects of htt on the respiration function and trafﬁcking of mitochon-
dria. In this review, we focus on the relationship between mutant htt
and mitochondria trafﬁcking as well as HD pathogenesis.2. Mitochondrial trafﬁcking
Mitochondria are the primary generators of ATP and are important
regulators of intracellular calcium homeostasis. Although the human
brain comprises 2% of total body mass, it consumes 20% of restingll rights reserved.metabolic energy [2]. Neurons are highly specialized cell types and
possess lengthy axons and dendrites that are highly branched and
constitute complex neural networks via synapses. Synaptic connec-
tions are highly plastic and undergo continuous remodeling to
modulate information processing [3,4]. Thus, neurons represent a
particular anatomical and physiological challenge for mitochondrial
trafﬁcking within neuronal processes and nerve terminals.
Mitochondria are dynamically transported along lengthy neuronal
processes to provide energy to nerve terminals and maintain the
normal neuronal function. Mitochondria are highly dynamic orga-
nelles that fuse and divide in neurons. The movement of mitochon-
dria also facilitates its fusion and ﬁssion events in neurons and
retrieval of damaged mitochondria for degradation by autophagy.
Although how mitochondria are transported and regenerated
remains to be understood, the failure to move mitochondria or
deliver mitochondria to appropriate sites in neurons would result in
energy starvation and impairment of neuronal interactions or neural
network function.
Mitochondrial movement in neurons is highly diverse and
complex. There are stationary and motile mitochondria, which
move with different speeds and in different directions [5]. Three
major groups of proteins are involved in transporting mitochondria
in neurons: (1) cytoskeletal microtubules and actin microﬁlaments,
(2) molecular motors, and (3) adaptor and scaffolding proteins that
link cargos to motors and the cytoskeleton. In neurons, micro-
tubules are likely to be tracks for transport over long distances
while actin microﬁlaments mediate travel over short distances. The
molecular motors, kinesins and cytoplasmic dynein, which are
ATPases, transport mitochondria toward (+)- and (−)-ends of
microtubules, respectively. It remains unclear how the cytoskeletal
substrates mediate the bidirectional and dynamic transport of
mitochondria.
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mediated by adaptor and scaffolding proteins. For example, Milton
and syntabulin are implicated as scaffolding proteins for linking
mitochondria with kinesin heavy chain [6,7]. Reducing the expression
of these proteins leads to abnormal distribution of mitochondria, as
expected from disrupted anterograde transport. APLIP1 is another
example of a scaffolding protein that may interact with both kinesin
and dynein to regulate retrograde transport of mitochondria [8]. Thus,
complex mitochondrial movements are likely mediated by various
and dynamic interactions between regulatory proteins, adaptors,
motors, and cytoskeletal elements.
3. Mitochondrial energy impairment in HD
The hypothesis that cellular energy production and metabolism
are compromised in HD was originally derived from clinical observa-
tions of both peripheral weight loss and central deﬁcits in brain
glucose utilization in HD patients [9,10]. Subsequent studies of
peripheral tissues from HD patients conﬁrmed the negative effect of
mutant htt on the energetic status in various cell types [11]. Analyses
of metabolic enzyme activity in post-mortem HD brain tissue have
consistently revealed deﬁcits in enzymes of the mitochondrial TCA
cycle and OXPHOS system. In particular, decreased complex II/III
activity and complex II (SDH) expression are seen in HD striatum but
not cortex or cerebellum [12–14].
Systemic administration of SDH inhibitors 3-nitropropionic acid
and malonate in rodents and non-human primates causes striatal
pathology and behavioral abnormalities reminiscent of HD [15].
Activities of several mitochondrial enzymes, including pyruvate
dehydrogenase, aconitase, SDH, and cytochrome oxidase, are sig-
niﬁcantly reduced in brain tissue from HD patients [11]. Following the
generation of genetic animal models of HD, several more speciﬁc
deﬁcits in mitochondrial function have been consistently observed.
ΔΨm, ATP production, Ca2+ handling, reactive oxygen species (ROS)
generation, and apoptotic induction are all altered in various HD
models [16]. However, the primacy of mitochondrial energetic
function in HD pathogenesis remains unclear. Of particular impor-
tance is the question of whether mitochondrial function is inﬂuenced
by the direct effect of mutant htt or via an indirect mechanism (e.g.
altered nuclear transcription).
It is known that mutant htt can accumulate in the nucleus to
interact with a number of transcription factors, leading to gene
transcriptional regulation [17]. Several recent studies highlight the
potential relevance of nuclear mutant htt on mitochondrial function.
Mutant htt has been shown to alter transcriptional activity of p53 and
PGC-1α, two nuclear factors that are known to indirectly regulate
mitochondrial function via their transcriptional activity [18–20].
In vitro studies indicate that ΔΨm and mitochondrial Ca2+
regulation are directly impaired by mutant htt and that increased
ROS generation is the driving force for these alterations [21–23].
Further, these studies demonstrate similar impairments in mitochon-
dria isolated from HD patients or mouse models and normal
mitochondria incubated with puriﬁed mutant proteins. These studies
also suggest that other mitochondrial abnormalities observed in HD
patients and model systems could be directly caused by mutant htt.
4. Mutant htt affects mitochondrial trafﬁcking
There is increased evidence that mutant htt can also affect the
trafﬁcking of mitochondria in neurons. Cortical neurons transfected
with mutant Htt display reducedmitochondrial trafﬁcking speciﬁcally
to cytoplasmic htt aggregates, and the degree of movement impair-
ment is correlated with the size of aggregates [24]. However,
abnormal mitochondrial motility was also observed in HD striatal
neurons in the absence of aggregates [25]. The effects of mutant htt on
mitochondrial movement support the early studies that htt plays anessential role in axonal transport in Drosophila [26] and that polyQ
expanded htt inhibits transport in squid axoplasm [27]. The trafﬁcking
function of htt is also indicated by its association with HAP1 [28].
HAP1 is a neuronal protein that is essential for neuronal function and
viability, as elimination of HAP1 leads to postnatal death of mice
[29,30]. HAP1 interacts with microtubule transporters dynactin p150
[31,32] and kinesin light chain [33]. The complex containing htt and
HAP1 may act as a docking platform to modulate vesicular cargo
attachment to both dynein/dynactin and kinesin microtubule motors
[34]. A HAP1 homolog in Drosophila, Milton, inﬂuences mitochondrial
distribution in axons through its interaction with the mitochondrial
protein Miro [35,36]. Also, htt may directly interact with trafﬁcking
proteins and acts as a molecular switch for bidirectional transport in
neurons [37].
Although there is compelling evidence that htt and its associated
proteins, such as HAP1, are involved in intracellular trafﬁcking, the
mechanisms by which mutant htt affects intracellular organelle
trafﬁcking remain to be fully understood. It is likely that an abnormal
interaction between mutant htt and HAP1 affects the trafﬁcking of
organelles in neurons by disrupting the formation of trafﬁcking
complexes and impairs vesicular transport in mammalian cells [38].
Mutant htt may also sequester wild type htt and trafﬁcking proteins to
impair neuronal trafﬁcking [25,26]. In addition, loss of the normal
function of htt can affect vesicular transport in neurons [26,34].
It is also possible that different htt forms differentially affect
intracellular trafﬁcking. It is possible that large htt aggregates can
physically block the neuronal trafﬁcking if their size exceeds the
narrow region of neuronal processes. However, it remains unclear
which form of soluble mutant htt is more harmful to the vesicular
transport in neurons. Htt is a large (350 kDa), predominantly
cytoplasmic protein that is a substrate for various proteolytic
enzymes. Proteolytic cleavage of full length mutant htt yields small
N-terminal fragments containing the polyQ domain that readily
misfold and aggregate in both neuronal nuclei and processes
[39,40]. The strong toxic property of proteolytically processed mutant
htt is evidenced by the more rapid disease progression of HD mice
expressing smaller N-terminal mutant htt fragments than that of mice
expressing full length mutant htt [41]. This phenomenon has led to
extensive study of the proteolysis of htt and the identiﬁcation of a
number cleavage sites in the N-terminal region of htt [42].
Using a knock-in mouse model of HD, we show that speciﬁc
N-terminal fragments, likely smaller than the ﬁrst 500 amino acids, of
mutant htt preferentially associate with mitochondria in vivo and that
N-terminal mutant htt fragments affect the trafﬁcking of mitochon-
dria [43]. This biochemical ﬁnding supports the recent subcellular
localization evidence that the ﬁrst 17 amino acids of htt are required
for localization of exon1 htt to mitochondria [44]. We also found age-
dependent accumulation of mutant htt on mitochondria and that this
accumulation directly correlates with disease progression. Finally, we
demonstrate that mitochondrial function can be disrupted by soluble
N-terminal mutant htt fragments independent of their nuclear
accumulation or aggregation [43]. Our observation of impaired
mitochondrial trafﬁcking and decreased ATP level in synaptosomes
caused by mutant htt suggests that impaired trafﬁcking of mitochon-
dria in neuronal processes can decrease mitochondrial ATP supply in
nerve terminals [45]. The decreased ATP level can also affect the
transport of mitochondria in neuronal processes. Together, these
ﬁndings suggest that abnormal interaction between mutant htt and
mitochondria may represent a cytoplasmic pathological event that
can serve as a therapeutic target for HD.
5. Impaired mitochondrial trafﬁcking and HD pathogenesis
Impaired mitochondrial transport probably has multiple con-
sequences that increase in severity with the duration of impaired
transport. Poor ATP distribution in nerve terminals is likely to be an
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mitochondria in a rapid and dynamic manner. These processes
include speciﬁc synaptic sites undergoing morphogenesis or poten-
tiation and are likely to actively recruit mitochondria under normal
conditions. Consistent with this idea, there are a reduced synaptic
ATP level and impaired activity of ubiquitin–proteasomal system
(UPS) in synapses of HD mice [43,45]. It is known that the UPS
function is largely dependent on ATP. Synaptic UPS may be more
vulnerable to impaired mitochondrial function or deﬁcient ATP
supplies in nerve terminals. Similarly, other nerve terminal func-
tions, such as neurotransmitter release and synaptic vesicle biogen-
esis, could also be affected if mitochondria transport to nerve
terminal is reduced by mutant htt. In addition, impairment of
mitochondrial movement may impede fusion-mediated mtDNA
complementation and autophagic degradation of damaged mito-
chondria [46,47].
As discussed above, neuronal function is particularly dependent on
the intracellular trafﬁcking of organelles and molecules over the long
distance of axons or neuronal processes. The unique anatomic
structures of neuronal processes may make neurons more vulnerable
to the impaired trafﬁcking caused by mutant htt, which also
contributes to the selective neurodegeneration in HD. However,
other polyglutamine disease proteins that largely accumulate in the
nucleus can also cause selective neurodegeneration via different
mechanisms. Because misfolded proteins preferentially accumulates,
in an age-dependent manner, in neuronal cells than in other types of
cells in all polyQ diseases, neuronal ability to remove misfolded polyQ
proteins is likely decreased by aging related factors. Indeed, age-
dependent decrease of UPS activity is more pronounced in neurons
than in glial cells [48]. It is also possible that the clearance of mutant
htt or damaged mitochondria by autophagy is decreased with age.
Once the cellular capacity to clear mutant polyQ proteins is decreased,
misfolded proteins can accumulate in the nucleus to affect gene
expression and in the neuronal processes to cause cytoplasmic
toxicity. In the case of HD, mutant htt has additional adverse effects
on intracellular trafﬁcking. Thus, the impaired trafﬁcking of mito-
chondria in neuronal processes and reduced ATP supply to nerve
terminals can lead to speciﬁc dysfunction of neurons.6. Conclusion
Recent studies have suggested several mechanisms for mitochon-
drial dysfunction in HD. These mechanisms can be classiﬁed as the
indirect effects of mutant htt via transcriptional dysregulation of
genes important for mitochondrial biogenesis and the direct effects of
mutant htt onmitochondria. Biochemical and cell biology studies have
provided strong evidence for the negative impact of mutant htt on
mitochondrial movement. Moreover, inhibition of the distribution of
mutant htt in neuronal processes by an intracellular antibody can
alleviate HD neurological symptoms in HD transgenic mice [49].
Because neuronal function is largely dependent on intracellular
trafﬁcking in lengthy processes and nerve terminals, the impaired
intracellular trafﬁcking in HD neurons is likely to contribute to the
speciﬁc neuropathology in HD. In addition, given that htt is
predominantly distributed in the cytoplasm, the cytoplasmic toxicity
of mutant htt could play an important role in HD pathology.
Understanding how mutant htt affects the transport of mitochondria
will help us to ﬁnd an effective means to reduce the selective
neuropathology in HD.Acknowledgements
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